<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We previously observed degranulated mast cells (MC) in association with perivascular <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation during focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Brain MC are typically located perivascularly and contain potent fast-acting vasoactive and proteolytic substances </plain></SENT>
<SENT sid="2" pm="."><plain>We examined in a rat model of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) whether, in the early phase of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, MC regulate microcirculation, the blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) permeability, and <z:hpo ids='HP_0000969'>edema</z:hpo> formation </plain></SENT>
<SENT sid="3" pm="."><plain>First, animals received MC inhibitor (cromoglycate), MC-degranulating drug (compound 48/80), or saline </plain></SENT>
<SENT sid="4" pm="."><plain>Thereafter, we performed transient MCAO in gene-manipulated MC-deficient rats and their <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) littermates, calculating <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e>, visualizing <z:chebi fb="2" ids="33602">BBB</z:chebi> leakage by intravenously administered Evans blue albumin, and determining neutrophil infiltration with light microscopy </plain></SENT>
<SENT sid="5" pm="."><plain>Cerebral blood flow, monitored by laser-Doppler flowmetry in separate experiments, was similar among pharmacological treatments </plain></SENT>
<SENT sid="6" pm="."><plain>Ischemic swelling resulted in increased hemispheric volume of 13.4%+/-1.0% in controls, 8.1%+/-0.4% (39% reduction) after cromoglycate, and 25.2%+/-2.0% (89% increase) after compound 48/80 (P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Early ischemic <z:chebi fb="2" ids="33602">BBB</z:chebi> leakage was reduced by 51% after cromoglycate, and 50% enhanced by compound 48/80 (P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>The cromoglycate group showed 37% less postischemic neutrophil infiltration than did controls (P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, MC-deficient rats responded to focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with 58% less <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e> (6.7%+/-1.2%) than did their WT littermates (15.8%+/-1.4%, P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Blood-brain barrier damage was 47% lower in MC-deficient rats than in the WT (P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>Neutrophil infiltration after MCAO was decreased 47% in MC-deficient rats in comparison to WT (P&lt;0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>Pharmacological MC inhibition thus appears to deserve further investigation regarding reduction of <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e> and <z:mp ids='MP_0001845'>inflammation</z:mp> early after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>